KIMMTRAK doubles the 5-yr survival rate for 1L HLA-A*02:01+ patients with metastatic uveal melanoma April 21, 2026
Positive Topline Results from Ph 2/3 Registrational Trial (OptimUM-02) of Darovasertib – Crizotinib combo in 1L HLA-A*02:01-neg Metastatic Uveal Melanoma Announced April 15, 2026
Full results from Ph 2 CHOPIN trial of percutaneous hepatic perfusion, ipilimumab, and nivolumab combo in metastatic uveal melanoma published in The Lancet Oncology March 10, 2026
Positive Interim Ph 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma Announced September 9, 2025
Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US September 3, 2025
US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma April 2, 2025
Positive Interim Ph 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma Announced October 1, 2024
